Newswise — Croissy-Beaubourg and Montpellier, February 3, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics andin vitro diagnostics, announces today that it has entered into a master services agreement with the biopharmaceutical company UCB, with a first application for the anti-TNF biologic certolizumab pegol (the brand name Cimzia®).
Under the terms of the master services agreement, Theradiag will perform services for UCB on a project basis. A first project has already been conducted to determine the comparability of Theradiag’s LISA TRACKER tests with tests performed by UCB in clinical trials for the monitoring of drug levels and anti-drug antibodies in human plasma. The results of this performance study confirmed the suitability of Theradiag’s theranostic kit for monitoring patients treated with certolizumab pegol. The study was sponsored by UCB.
“We are extremely pleased to have entered into this services agreement with UCB, one of the leading biopharmaceutical companies engaged in the treatment of auto-immune diseases. The success of the performance study shows that LISA TRACKER tests could potentially be included in pharmaceutical clinical trials in the future. This is excellent news for our research teams who have developed the theranostics kits, as well as for our investors, since this agreement constitutes a driver of growth for Theradiag’s theranostics sales in Europe and the rest of the world” commented Michel Finance, Chief Executive Officer of Theradiag.
To read more information please click on this link to view the full THERADIAG and UCB enter into a master services agreement
RSS